Arthritis care & research
Sarilumab in Polyarticular-Course Juvenile Idiopathic Arthritis: Dose-Finding and One-Year Analysis of a Phase 2b, Open-Label, Multicenter Study.
Fabrizio De Benedetti, Inmaculada C Penadés, Irina Nikishina, Ivan Foeldvari, Alberto J Spindler, Anna Kozlova, Nadina Rubio-Pérez, Pierre Quartier, Zbigniew Żuber, Raul Barria, Daniel Clemente, Gabriel V Cornejo, Katherine Marzan, Nancy Liu, Christine Xu
Published: 202510.1002/acr.25692
Abstract
OBJECTIVE: This study assessed sarilumab in treating patients with polyarticular-course juvenile idiopathic arthritis (pcJIA). METHODS: This phase 2b, open-label study (NCT02776735) consisted of three sequential parts (each with a core-treatment and…
Preview only. Read the full abstract at the source